Loading organizations...
Ceram Pharmaceuticals is a biotechnology firm focused on the research and development of cancer therapeutics and diagnostic tools utilizing epigenetic mechanisms. The organization operates within the oncology sector, aiming to address malignancies through targeted approaches that modify gene expression rather than altering the underlying DNA sequence. By leveraging advancements in epigenetic science, the company seeks to identify specific biomarkers that aid in the early detection and monitoring of oncological conditions. The firm's therapeutic pipeline centers on developing proprietary compounds designed to disrupt the abnormal epigenetic patterns frequently associated with tumor growth and cancer progression. The enterprise remains engaged in ongoing research phases to validate the clinical efficacy of its specialized diagnostic assays and targeted drug candidates. Specific details regarding the company's headquarters location, total funding raised, institutional investors, founding year, and original founders are not currently publicly disclosed.
Ceram Pharmaceuticals has raised $45.4M across 2 funding rounds.
Ceram Pharmaceuticals has raised $45.4M in total across 2 funding rounds.
Ceram Pharmaceuticals has raised $45.4M across 2 funding rounds. Most recently, it raised $14.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 25, 2023 | $14M Series A | — | — | Announced |
| Jan 4, 2022 | $31.4M Series A | CDH Investments | Dawu Venture Capital, Kaitai Capital | Announced |
Ceram Pharmaceuticals has raised $45.4M in total across 2 funding rounds.
Ceram Pharmaceuticals's investors include CDH Investments, Dawu Venture Capital, Kaitai Capital.
